In vivo CRISPR/Cas9 targeting of fusion oncogenes for selective elimination of cancer cells
Fusion oncogenes (FO) are common in cancers, but specific targeting of these chimeric genes are challenging. Here the authors report a CRISPR/Cas9 strategy that targets two intronic regions to disrupt the FOs in cancer cells and show that this approach reduces tumour growth and prolongs survival in...
Main Authors: | M. Martinez-Lage, R. Torres-Ruiz, P. Puig-Serra, P. Moreno-Gaona, M. C. Martin, F. J. Moya, O. Quintana-Bustamante, S. Garcia-Silva, A. M. Carcaboso, P. Petazzi, C. Bueno, J. Mora, H. Peinado, J. C. Segovia, P. Menendez, S. Rodriguez-Perales |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2020-10-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/s41467-020-18875-x |
Similar Items
-
CRISPR/Cas9 for Cancer Therapy: Hopes and Challenges
by: Marta Martinez-Lage, et al.
Published: (2018-11-01) -
CRISPR/Cas9-mediated targeted chromosome elimination
by: Erwei Zuo, et al.
Published: (2017-11-01) -
The small, slow and specialized CRISPR and anti-CRISPR of Escherichia and Salmonella.
by: Marie Touchon, et al.
Published: (2010-06-01) -
Efficient Recreation of t(11;22) EWSR1-FLI1+ in Human Stem Cells Using CRISPR/Cas9
by: Raul Torres-Ruiz, et al.
Published: (2017-05-01) -
Novel combination of CRISPR-based gene drives eliminates resistance and localises spread
by: Nicky R. Faber, et al.
Published: (2021-03-01)